What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?

Psoriatic arthritis is a heterogeneous disease and the choice of therapy is driven by many factors.

The most important factors in the decision tree are whether the patient has 1) axial disease and/or 2) severe psoriasis.

Additional Considerations include: prior therapies, extramusculoskeletal manifest...

I assume the question means, why would you select an oral IL-23 inhibitor over OTHER oral systemic options for psoriasis/psoriatic arthritis? There is a lot of excitement over the oral IL-23 inhibitor data, but this therapy is not currently FDA-approved therapy. Once approved, there will be a lot of...